Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Telegram Restored on Apple App Store After Temporary Removal 
WATERTOWN, Mass., April 02, 2018 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the H. C. Wainwright Annual Global Life Sciences Conference on Monday, April 9 at 10:40 a.m. CEST at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Live audio webcasts of the presentation will be available on the company’s website at http://ir.tphase.com/events.cfm. Archived presentations will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multi-drug resistant pathogens highlighted as urgent public health threats by the Centers for Disease Control and Prevention. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which has completed phase 3 clinical trials and is under review for potential approval in complicated intra-abdominal infections by the United States Food and Drug Administration and the European Medicines Agency, and TP-271 and TP-6076, which are in phase 1 clinical trials. Eravacycline is an investigational product only and has not been approved for commercialization. Please visit www.tphase.com for more company information.
Investor Contacts:
Tetraphase Pharmaceuticals
Jennifer Viera
617-600-7040
[email protected]
Argot Partners
Maeve Conneighton
206-899-4940
[email protected]
Media Contact:
Sam Brown Inc.
Mike Beyer
312-961-2502
[email protected]
###
